Company intelligence / Profile preview

Acorda Therapeutics

Pearl River, New York, United Statesacorda.com ↗

Ownership: Public · ACOR
Employees: ~344
Development stage: Commercial

Overview

Acorda developed two FDA-approved commercial products—Ampyra® for MS-related walking impairment and Inbrija® for Parkinson’s OFF episodes. Both drugs demonstrated efficacy in pivotal trials leading to regulatory approval. The company also advanced a pipeline including a remyelinating antibody program and an inhaled migraine therapy using its proprietary ARCUS platform. As of July–August 2024, all commercial products and key technologies were sold to Merz Therapeutics following Chapter 11 bankruptcy proceedings.

Therapeutic areas: GastroenterologyNeurology
Modalities: Small molecules (dalfampridine/Ampyra)Inhaled therapeutics (levodopa/Inbrija via ARCUS technology)Monoclonal antibodies (rHIgM22 for MS remyelination)Biologics/antibodies (timolumab/BTT1023)
Industry: Biotech

Drug pipeline

7 assets

levodopa inhalation powder

Approved

6 more assets in the full pipeline.

Request access →

Partnerships

Biogen Inc.—collaboration/license agreement on Ampyra/Fampyra development/commercialization [3][4]Chance Pharmaceuticals Co. Ltd.—distribution agreement for INBRIJA in China [2]Biopas Laboratories—commercialization/distribution agreement for INBRIJA in Latin America [2]

Financials

Market cap: $821K
Total revenue: $20.3M
Enterprise value: $187.4M

Beyond the preview

Go deeper on Acorda Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acorda Therapeutics.

Explore the full profile